UnitedHealthcare
Rydapt (midostaurin)
Drugs for Cancer : Drugs for Cancer
  • Ovarian Cancer:
    Age Requirement: >= 18
    Duration: 12 Month(s)
    Specialist Required: Yes
    Documented Diagnosis: Yes
    Medical Test Required: Yes
    Specialist Type(s): Oncologist
    Reauthorization Required: Yes
    Duration of Reauthorization: <= 12 month(s)
    Drug Policy Based On: 1 of FDA Approved Indications;NCCN Guidelines
    Diagnosis Types: 2 of All FDA-approved indications;as a single agent;deleterious or suspected deleterious germline and/or somatic BRCA mutation;epithelial ovarian, fallopian tube, or primary peritoneal cancer;maintenance treatment after a complete or partial response to platinum-based chemotherapy;Treated with at least 2 prior lines chemotherapy;Treated with at least 2 prior lines of platinum based chemotherapy
    Supporting Documentation Requirements: 2 of Chart Notes;Lab Tests

  • PA_APPLIES
  • Step Therapy: ST_APPLIES
  • Quantity Limit: 204 lancets per 30 day(s).